Drug Profile
Research programme: histamine H3 receptor antagonists - Merck/Banyu
Alternative Names: 5RLatest Information Update: 29 Aug 2011
Price :
$50
*
At a glance
- Originator Banyu; Merck & Co
- Class Benzofurans; Quinazolinones
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 29 Aug 2011 No development reported - Preclinical for CNS disorders in Japan (PO)
- 21 Aug 2008 Preclinical trials in CNS disorders in Japan (PO)